Connect Biopharma Holdings Ltd. - 10-K Summary (Fiscal Year Ended Dec 31, 2025)
Business Context and Reporting Period
Company: Connect Biopharma Holdings Ltd (CNTB)
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Clinical-stage biopharmaceutical company focused on respiratory diseases (asthma and COPD).
Lead Asset: Rademikibart, a next-generation antibody targeting IL-4Rα.
Key Partnership: Exclusive license agreement with Simcere Pharmaceutical Co., Ltd. for development and commercialization in Greater China.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $64 | $26,033 |
| Net Loss | $(55,480) | $(15,628) |
| Operating Expenses | $58,138 | $48,485 |
| Cash, Cash Equivalents & Short-Term Investments | $44,342 | $93,708 |
| Accumulated Deficit | $(400,835) | $(345,355) |
| Net Cash Used in Operating Activities | $(51,206) | $(23,612) |
Note: Revenue in 2025 consisted primarily of $64,000 in cost reimbursements. 2024 revenue included a $21 million upfront payment and milestone payments from the Simcere agreement.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 99.8% year-over-year due to the recognition of the Simcere upfront fee and milestones in 2024, with only minor cost reimbursements recognized in 2025.
- Increased Loss: Net loss increased by $39.9 million (255%) driven by higher Research and Development (R&D) expenses ($37.8M vs $29.3M) as the company initiated Phase 2 trials for acute asthma and COPD.
- Cash Burn: Net cash used in operating activities more than doubled to $51.2 million, reflecting increased operational scale and lower non-cash share-based compensation.
- Liquidity Position: Total cash and short-term investments decreased by approximately $49 million to $44.3 million.
Guidance, Outlook, and Risks
Clinical Outlook:
- Phase 2 Trials: Initiated in Q2 2025 for acute exacerbations of asthma and COPD. Topline data expected in mid-2026.
- Phase 1 Data: March 2026 announcement of positive Phase 1 data showing rapid improvement in lung function (FEV1) within 15 minutes of IV administration.
- China Partner: Simcere submitted a New Drug Application (NDA) for rademikibart for Atopic Dermatitis (AD) in China in July 2025. Positive Phase 3 AD data announced in March 2026.
Liquidity and Capital:
- Private Placement: In March 2026, the company entered into an agreement for a private placement of 6.1 million shares, expected to generate gross proceeds of $20.2 million (net ~$18.6 million).
- Runway: Management expects current cash plus private placement proceeds to fund operations for at least one year from the filing date.
Key Risks:
- Capital Requirements: The company has incurred significant losses since inception and will require substantial additional financing to complete development and commercialization.
- Regulatory Uncertainty: Risks associated with clinical trial outcomes, regulatory approvals (FDA, NMPA), and potential delays.
- Geopolitical & Legal: Operations in the PRC expose the company to regulatory changes, data security laws, and potential trade restrictions (e.g., BIOSECURE Act).
- Single Product Dependence: Business success relies entirely on the development of rademikibart.
Investor Verification Checklist
- Capital Adequacy: Verify the closing of the March 2026 private placement and confirm the net proceeds received.
- Clinical Milestones: Monitor the timeline for mid-2026 topline data release from the Phase 2 acute asthma and COPD trials.
- China Regulatory Status: Track the status of Simcere's NDA for Atopic Dermatitis in China and any subsequent regulatory feedback.
- Burn Rate: Assess quarterly cash burn rates to determine if the projected 12-month runway remains valid given current spending levels.
- Geopolitical Exposure: Review updates on U.S. regulations regarding biotechnology companies with PRC operations (e.g., BIOSECURE Act) and their potential impact on supply chains or funding.